

**MOLECULAR PARTNERS TO PRESENT NEW DATA ON IMMUNO-ONCOLOGY PIPELINE
AT UPCOMING SCIENTIFIC CONFERENCES**

Zurich-Schlieren, November 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the company plans to participate in several upcoming scientific conferences in November and December 2018. At these conferences listed below, members of the Molecular Partners team will present updated research and preclinical data on the company's DARPin® "toolbox" as well as on MP0310, its most advanced multi-specific (FAP x 4-1BB) DARPin® immuno-oncology compound, and on FAP x CD40, a second multi-specific DARPin® immuno-oncology compound.

33th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Washington D.C., November 9-10, 2018

Focus: (1) MP0310 (FAP x 4-1BB); (2) FAP x CD40 candidate

Titles: (1) Preclinical identification of the pharmacologically active dose range of the tumor-targeted 4-1BB agonist MP0310 based on tumor regression, receptor occupancy and CD8 T lymphocyte expansion; (2) Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® molecule for tumor-restricted immune activation

EORTC-NCI-AACR 2018

Dublin, November 14, 2018

Focus: FAP x CD40 candidate

Title: Bispecific CD40/FAP DARPin® molecule for tumor-restricted immune activation

PEGS Europe

Lisbon, November 16, 2018

Focus: MP0310 (FAP x 4-1BB)

Title: Tumor-targeted DARPin® drug candidates for tumor-restricted immune cell co-activation

4th Annual ICI Europe Summit

Berlin, November 29, 2018

Focus: FAP x CD40 candidate

Title: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® protein for tumor-localized immune activation

Tumor Models London Meeting

London, December 6, 2018

Focus: MP0310 (FAP x 4-1BB)

Title: Preclinical animal models for therapeutic clinical dose predictions and PD assessment

IBC Antibody Engineering & Therapeutics

San Diego, December 13, 2018

Focus: MP0310 (FAP x 4-1BB)

Title: Cancer therapy revisited

The corresponding posters and/or presentations will be available on the company's webpage after they are presented. Please visit the [scientific presentations section of Molecular Partners' website](#).

Financial Calendar

December 6, 2018	R&D Day in New York
February 7, 2019	Publication of Full-year Results 2018 (unaudited)
March 15, 2019	Expected Publication of Annual Report 2018
April 16, 2019	Annual General Meeting
May 9, 2019	Interim Management Statement Q1 2019
August 27, 2019	Publication of Half-year Results 2019 (unaudited)
October 31, 2019	Interim Management Statement Q3 2019

<http://investors.molecularpartners.com/financial-calendar-and-events/>

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPIn® therapeutics. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 44 755 77 00

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

Thomas Schneckenburger, IR Europe
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Susan A. Noonan, IR USA
susan@sanoonan.com
Tel.: +1 212 966 3650

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.